Antares Pharma (NYSE:AIS) has licensed its newly approved overactive bladder gel to South Korea pharmaceutical company Daewoong Pharmaceuticals Co. in a move that will bring the drug to the Asian market. Ewing, New Jersey-based Antares will receive undisclosed up-front payments, regulatory milestones and sales-based milestones, as well as royalties on net sales for the product, […]
Antares Pharma (AMEX:AIS) has inked a licensing agreement with Pfizer (NYSE:PFE) to provide one of its drug-delivery technologies to Pfizer’s consumer healthcare business arm for an unnamed product for North America. Pfizer, in New York, will be responsible for clinical development, manufacturing and commercialization of the product. Ewing, New Jersey-based Antares will receive up-front payments, […]
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
A gel developed by Antares (AMEX:AIS) and licensed to BioSante Pharmaceuticals (NASDAQ:BPAX) to treat female sexual dysfunction failed two phase 3 clinical trials testing efficacy, according to a statement from BioSante. Initial analysis of the data from the trials showed that the tests “did not meet the co-primary or secondary endpoints,” the statement said. LibiGel […]
Antares Pharma (AMEX:AIS) broke through last week with FDA approval of a topical gel to treat overactive bladder. It’s a cash win for the New Jersey company, which will receive royalties from sales and milestone payments for delivery of the drug — called Anturol — to Watson Pharmaceuticals (NYSE:WPI), which will commercialize the product next […]